Axovant Sciences Ltd. | |
Stock Exchange | New York Stock Exchange |
EPS |
$1.89 |
Market Cap |
$247.82 M |
Shares Outstanding |
122.08 M |
Public Float |
32.13 M |
Address |
11-12 St. James's Square London London & South East SWIY 4LB United Kingdom |
Employees | - |
Website | http://www.axovant.com |
Updated | 09/14/2018 |
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel therapeutics in the fields of neurology and psychiatry. Its therapeutic focus are Parkinson's Disease and Lewy Body Dementia. It operates through the following geographical sgements: United States, Switzerland, Bermuda, and Other. |